Project: Gene Therapy for Cerebellar Ataxias: restoring cholesterol metabolism by targeting brain cholesterol 24 hydroxylase (CYP46A1)
| Acronym | SCA-CYP |
| Duration | 01/06/2018 - 01/06/2021 |
| Project Topic | Impaired brain cholesterol metabolism plays a major role in neurodegenerative diseases like Parkinson (PD), Alzheimer (AD) and Huntington (HD). By transforming cholesterol into 24-HydroxyCholesterol (24-OHChol), CYP46A1 is a neuronal key enzyme that allows exporting cholesterol out of the brain therefore activating cholesterol turnover. We demonstrated that CYP46A1 is decreased in brains of AD and HD patients and mice. Moreover, 24-OHChol was reproductively decreased in the plasma of HD patients. Overexpressing CYP46A1 in affected brain regions using an Adeno-Associated Virus (AAV) vector corrects murine models of AD and HD. Importantly, it decreases aggregation of polyQ-mutated Huntingtin. Our preliminary data show that 1) both CYP46A1 and 24OHChol are decreased in the affected cerebellum of a transgenic mouse model of polyQ cerebellar ataxia and CYP46A1 is decreased in the cerebellum of ScA3 patients; 2) AAVCYP46A1 overexpression in a lentiviral-mouse model of SCA3 significantly decreases PolyQ aggregates and prevents neuronal death. Our objectives are 1) to confirm the role of cholesterol metabolism dysfunction in polyQ Spinocerebellar Ataxias (SCAs) and 2) demonstrate the efficacy of an AAVCYP46A1 gene therapy strategy in these disorders for which no efficient therapeutic option is available. |
| Network | E-Rare-3 |
| Call | 9th JOINT CALL FOR EUROPEAN RESEARCH PROJECTS ON RARE DISEASES (JTC 2017) |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | INSERM | Coordinator | France |
| 2 | Polish Academy of sciences | Partner | Poland |
| 3 | University of Tuebingen | Partner | Germany |
| 4 | University of Coimbra | Partner | Portugal |
| 5 | INSERM | Partner | France |